A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma

Xiaohong Han, Yuankai Shi, Huaqing Wang et al.|Chinese Journal of Cancer Research|2022

Cited by 5